Literature DB >> 23714479

How do mechanisms of hepatocarcinogenesis (HBV, HCV, and NASH) affect our understanding and approach to HCC?

Philip J Johnson1.   

Abstract

The major etiologic factors for hepatocellular carcinoma (HCC), including chronic hepatitis B and C virus infections and nonalcoholic fatty liver disease, are now well established by epidemiologic investigations. The mechanisms by which these factors result in HCC have been extensively investigated but have not, to date, resulted in the development of specific therapeutic interventions. Other frequently occurring dysregulated pathways, including the Wnt/β-catenin signaling pathway, are proving difficult to target, but there are early suggestions that patients with "MET-high" HCC may benefit from the c-MET inhibitor tivantinib. Chronic inflammation and consequent cell damage and regenerative proliferation are common to all etiologic factors, and emerging evidence suggests that anti-inflammatory agents such as aspirin deserve further investigation as preventive agents.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23714479     DOI: 10.1200/EdBook_AM.2013.33.e132

Source DB:  PubMed          Journal:  Am Soc Clin Oncol Educ Book        ISSN: 1548-8748


  6 in total

Review 1.  Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?

Authors:  Liliana Montella; Giovannella Palmieri; Raffaele Addeo; Salvatore Del Prete
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

2.  Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice.

Authors:  Xingkai Liu; Ping Zhang; Robert C Martin; Guozhen Cui; Guangyi Wang; Yi Tan; Lu Cai; Guoyue Lv; Yan Li
Journal:  Am J Cancer Res       Date:  2016-05-01       Impact factor: 6.166

3.  OATP1B3 Expression in Hepatocellular Carcinoma Correlates with Intralesional Gd-EOB-DTPA Uptake and Signal Intensity on Gd-EOB-DTPA-Enhanced MRI.

Authors:  Xiaojiao Zhou; Liling Long; Zhiqing Mo; Yajuan Li
Journal:  Cancer Manag Res       Date:  2021-02-09       Impact factor: 3.989

Review 4.  Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review.

Authors:  Wei-Xun Chen; Gan-Xun Li; Zheng-Nan Hu; Peng Zhu; Bi-Xiang Zhang; Ze-Yang Ding
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

Review 5.  Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.

Authors:  Mohamed Bouattour; Eric Raymond; Shukui Qin; Ann-Lii Cheng; Uz Stammberger; Giuseppe Locatelli; Sandrine Faivre
Journal:  Hepatology       Date:  2018-02-01       Impact factor: 17.425

Review 6.  Metabolic syndrome and liver disease in the era of bariatric surgery: What you need to know!

Authors:  Ioannis A Ziogas; Konstantinos Zapsalis; Dimitrios Giannis; Georgios Tsoulfas
Journal:  World J Hepatol       Date:  2020-10-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.